The anti-Bcl-2 drug ABT-199/Venetoclax is a promising anti-CLL agent that demonstrated potent clinical activity also in CLL cases with poor prognosis25. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.